Microbot Medical Stock Debt To Equity
| CY9D Stock | EUR 0.92 0.01 1.08% |
Microbot Medical fundamentals help investors to digest information that contributes to Microbot Medical's financial success or failures. It also enables traders to predict the movement of Microbot Stock. The fundamental analysis module provides a way to measure Microbot Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Microbot Medical stock.
Microbot |
Microbot Medical Company Debt To Equity Analysis
Microbot Medical's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Microbot Medical Debt To Equity | 0.04 % |
Most of Microbot Medical's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Microbot Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Microbot Medical has a Debt To Equity of 0.035%. This is 99.93% lower than that of the Healthcare sector and 99.94% lower than that of the Medical Instruments & Supplies industry. The debt to equity for all Germany stocks is 99.93% higher than that of the company.
Microbot Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Microbot Medical's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Microbot Medical could also be used in its relative valuation, which is a method of valuing Microbot Medical by comparing valuation metrics of similar companies.Microbot Medical is currently under evaluation in debt to equity category among its peers.
Microbot Fundamentals
| Return On Equity | -1.2 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 25.69 M | |||
| Shares Outstanding | 7.89 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.65 % | |||
| Price To Book | 5.90 X | |||
| EBITDA | (11.28 M) | |||
| Net Income | (11.31 M) | |||
| Cash And Equivalents | 20.62 M | |||
| Cash Per Share | 2.90 X | |||
| Total Debt | 708 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 17.41 X | |||
| Book Value Per Share | 0.78 X | |||
| Cash Flow From Operations | (9.35 M) | |||
| Earnings Per Share | (1.76) X | |||
| Number Of Employees | 20 | |||
| Beta | 3.26 | |||
| Market Capitalization | 20.07 M | |||
| Total Asset | 16.77 M | |||
| Z Score | 16.8 | |||
| Net Asset | 16.77 M |
About Microbot Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Microbot Stock
When determining whether Microbot Medical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Microbot Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Microbot Medical Stock. Highlighted below are key reports to facilitate an investment decision about Microbot Medical Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Microbot Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Microbot Stock please use our How to Invest in Microbot Medical guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.